A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY ISSN： 1758-8340 出版频率： Continuous publication 出版社： SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP   出版社网址： http://www.uk.sagepub.com/home.nav 期刊网址： http://www.uk.sagepub.com/journalsProdDesc.nav?prodId=Journal201920&ct_p=title&crossRegion=asia 影响因子： 8.168 主题范畴： ONCOLOGY 变更情况： Newly Added by 2014 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Therapeutic Advances in Medical Oncology Frequency: Published 6 times a year eISSN: 1758-8359 ISSN: 1758-8340 Months of Distribution: January , March , May , July , September , November 2013 Unofficial Impact Factor: 1.966 Source: Based on data from Thomson Reuters Web of KnowledgeSM Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of oncology, including chemotherapy, endocrine therapy, biological therapy and immunotherapy, as well as adjuvant systemic therapy. All cancers are covered including gynaecological cancers, lung cancer, gastrointestinal cancers, urological cancers, head and neck cancers, and skin cancer. It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online. For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact: Commercial Sales Team, London, UK Tel. +44 20 7336 1205 Email. reprints@sagepub.co.uk This journal is a member of the Committee on Publication Ethics (COPE). Aims & Scope The Journal is aimed at researchers and clinicians involved in the medical treatment of cancer and is a forum for publishing original research and reviews in this area. It covers systemic cancer treatments including chemotherapy, endocrine therapy, biological therapy and immunotherapy, as well as adjuvant systemic therapy. All cancers are covered including gynaecological cancers, lung cancer, gastrointestinal cancers, urological cancers, head and neck cancers, and skin cancer. Therapeutic Advances in Medical Oncology adheres to a blinded peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Rapid Peer Review Process: Each research article and review manuscript is reviewed by at least two referees. All manuscripts are reviewed as rapidly as possible, and a first editorial decision is generally reached within 3 weeks of submission. 1. The purpose of the Journal is to publish (in the English language) articles, reviews and scholarly comment (judged worthy of publication by appropriate specialists and accepted by the Editor) relating to medical oncology. The Journal is for all professionals and is a forum for all views on related subjects. The editorial board welcomes articles of current interest on original research, reviews and clinical studies. 2. The Journal will be international in the sense that it will seek, wherever possible, to publish material from authors with an international reputation and articles that are of interest to an international audience. 3. In pursuit of the above the journal shall: (i) draw on and include high quality work from the international community of scholars including those in the major countries of Europe, Australasia, the United States, other parts of the Americas, countries in the Third World and elsewhere with due representation for considerations of the readership. The Journal shall include work representing the major areas of interest in contemporary research in medical oncology. (ii) avoid bias in favour of the interests of particular schools or directions of research or particular political or narrow disciplinary objectives to the exclusion of others; (iii) ensure that articles are written in a terminology and style which makes them intelligible, not merely within the context of a particular discipline or abstract mode, but across the domain of relevant disciplines. Abstracting/Indexing Chemical Abstracts Service (CAS)  Medscape  PubMed  Scopus Instructions to Authors Manuscript Submission Correspondence and online submission Publication categories Writing your manuscript  Reference style 4.1 Corresponding author contact details Research ethics Publication statement Peer review statement Journal contributor’s publishing agreement Declaration of conflicting interests policy Authorship Funding Acknowledgement Informed consent Permissions After acceptance 10.1 Proofs 10.2 E-Prints and complimentary copies 10.3 SAGE production 10.4 OnlineFirst publication 10.5 SAGE Choice Editorial Board Editor: Gordon Mallarkey SAGE Publications Ltd, UK Associate Editors: Michael Friedlander Prince of Wales Hospital, Randwick, NSW, Australia Rene Gonzalez University of Colorado, Aurora, CO, USA Axel Grothey Mayo Clinic, Rochester, MN, USA Derek Raghavan Levene Cancer Institute, Charlotte, NC, USA Frances A Shepherd Princess Margaret Hospital, Toronto, ON, Canada   Editorial Board: Dr. Dirk Arnold Tumor Biology Center, Freiburg, Germany Carlos L Arteaga Vanderbilt University, Nashville, TN, USA Christopher Benz Buck Institute for Age Research, Novato, CA, USA Michael Boyer University of Sydney, Sydney, Australia Kim N Chi University of British Columbia, Vancouver, BC, Canada Toni K Choueiri Dana-Farber Cancer Institute, Boston, MA, USA Ronald de Wit Erasmus University Rotterdam, Rotterdam, The Netherlands Tanya B. Dorff USC Keck School of Medicine, Los Angeles, CA, USA Wilfried Eberhardt University Duisburg-Essen, Essen, Germany Tim Eisen Cambridge University, Cambridge, UK Alfredo Falcone University of Pisa, Livorno, Italy Michael Findlay University of Auckland, Auckland, New Zealand Jorge A. Garcia Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA Cesare Gridelli S.G. Moscati Hospital, Avellino, Italy Nasser H. Hanna Indiana University - Purdue University, Indianapolis, IN, USA Paul R Helft Indiana University School of Medicine, Indianapolis, IN, USA Maha Hussain University of Michigan, Ann Arbour, MI, USA David H Ilson Memorial Sloan-Kettering Cancer Center, New York, NY, USA Sung-Bae Kim University of Ulsan, South Korea James Larkin Royal Marsden Hospital, London, UK Robert R McWilliams Mayo Clinic, Rochester, MN, USA Sofia Merajver University of Michigan, Ann Arbour, MI, USA Mark Middleton Oxford University, Oxford, UK Nevin Murray British Columbia Cancer Agency, Canada Paul Nathan Mount Vernon Cancer Centre, Northwood, UK Sylvie Negrier Centre Léeon-Béerard, Lyon, France Harvey I Pass New York University, New York, NY, USA Edith A Perez Mayo Clinic, Jacsonville, FL, USA Robert Pirker Medical University of Vienna, Vienna, Austria Emilio Porfiri Birmingham University, Birmingham, UK David Quinn University of Southern California, Los Angeles, CA, USA Joseph D Rosenblatt University of Miami, Miami, FL, USA Josep Tabernero Vall d'Hebron University Hospital, Barcelona, Spain Scott T. Tagawa   Toni Wozniak Wayne State University, Detroit, MI, USA Andrew X Zhu Massachusetts General Hospital Cancer Center, Boston, MA, USA